SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (date of earliest event reported): February 14, 2002
RIGEL PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
| Delaware (State of jurisdiction) |
0-29889 (Commission File No.) |
94-3248524 (IRS Employer Identification No.) |
240 East Grand Avenue, South San Francisco, CA 94080
(Address of principal executive offices and zip code)
(650) 624-1100
Registrant's telephone number, including area code:
On February 14, 2002, Rigel Pharmaceuticals, Inc. commenced the offering of up to 465,117 shares of its common stock at $4.30 per share and pursuant to its Form S-3 shelf registration statement.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits
(c) Exhibits
| Number |
Description |
|
|---|---|---|
1.1 |
Form of Placement Agency Agreement by and between Rigel Pharmaceuticals, Inc. and Robertson Stephens, Inc. |
|
5.1 |
Opinion of Cooley Godward LLP. |
|
23.1 |
Consent of Cooley Godward LLP. Reference is made to Exhibit 5.1. |
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| RIGEL PHARMACEUTICALS, INC. | ||||
Dated: February 14, 2002 |
By: |
/s/ James H. Welch James H. Welch Vice President, Chief Financial Officer and Secretary |
||
| Number |
Description |
|
|---|---|---|
1.1 |
Form of Placement Agency Agreement by and between Rigel Pharmaceuticals, Inc. and Robertson Stephens, Inc. |
|
5.1 |
Opinion of Cooley Godward LLP. |
|
23.1 |
Consent of Cooley Godward LLP. Reference is made to Exhibit 5.1. |